Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Oric Pharmaceuticals, Inc. (ORIC : NSDQ)
 
 • Company Description   
ORIC Pharmaceuticals Inc. is a clinical stage oncology company. It is focused on developing treatments which address mechanisms of therapeutic resistance. The company's product candidate consists of ORIC-101 and ORIC-533 which are in clinical stage. ORIC Pharmaceuticals Inc. is based in San Francisco, United States.

Number of Employees: 115

 
 • Price / Volume Information   
Yesterday's Closing Price: $10.80 Daily Weekly Monthly
20 Day Moving Average: 1,013,854 shares
Shares Outstanding: 85.22 (millions)
Market Capitalization: $920.42 (millions)
Beta: 1.54
52 Week High: $14.67
52 Week Low: $3.90
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week 17.90% 11.52%
12 Week 150.58% 110.22%
Year To Date 33.83% 25.35%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
240 E. GRAND AVE. 2ND FLOOR
-
SOUTH SAN FRANCISCO,CA 94080
USA
ph: 650-388-5600
fax: -
investors@oricpharma.com http://www.oricpharma.com
 
 • General Corporate Information   
Officers
Jacob M. Chacko - Chief Executive Officer and President
Richard Heyman - Chairman
Dominic Piscitelli - Chief Financial Officer
Mardi Dier - Director
Steven Hoerter - Director

Peer Information
- (-)
- (-)
- (-)
- (-)
- (-)
- (-)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 68622P109
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/25
Next Expected EPS Date: 08/11/25
Share - Related Items
Shares Outstanding: 85.22
Most Recent Split Date: (:1)
Beta: 1.54
Market Capitalization: $920.42 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.44 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-1.75 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 6.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/11/25  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 3.49
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: -13.51%
vs. Previous Quarter: 17.65%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
ROE
06/30/25 - -
03/31/25 - -51.14
12/31/24 - -44.54
ROA
06/30/25 - -
03/31/25 - -46.29
12/31/24 - -40.72
Current Ratio
06/30/25 - -
03/31/25 - 12.00
12/31/24 - 10.56
Quick Ratio
06/30/25 - -
03/31/25 - 12.00
12/31/24 - 10.56
Operating Margin
06/30/25 - -
03/31/25 - -
12/31/24 - -
Net Margin
06/30/25 - -
03/31/25 - -
12/31/24 - -
Pre-Tax Margin
06/30/25 - -
03/31/25 - -
12/31/24 - -
Book Value
06/30/25 - -
03/31/25 - 3.09
12/31/24 - 3.45
Inventory Turnover
06/30/25 - -
03/31/25 - -
12/31/24 - -
Debt-to-Equity
06/30/25 - -
03/31/25 - 0.00
12/31/24 - 0.00
Debt-to-Capital
06/30/25 - -
03/31/25 - 0.00
12/31/24 - 0.00
 

Powered by Zacks Investment Research ©